Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents. [electronic resource]
Producer: 20180720Description: 1798-1804 p. digitalISSN:- 1463-1326
- Body Mass Index
- Diabetes Mellitus, Type 2 -- complications
- Disease Progression
- Drug Combinations
- Drug Resistance
- Drug Therapy, Combination -- adverse effects
- Glucagon-Like Peptide-1 Receptor -- metabolism
- Glycated Hemoglobin -- analysis
- Humans
- Hyperglycemia -- prevention & control
- Hypoglycemia -- chemically induced
- Insulin Glargine -- administration & dosage
- Middle Aged
- Obesity -- complications
- Peptides -- administration & dosage
- Postprandial Period
- Weight Gain -- drug effects
- Glucagon-Like Peptide-1 Receptor Agonists
No physical items for this record
Publication Type: Comparative Study; Equivalence Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.